Pharmaceutical capital allocation is undergoing a rapid recalibration following unprecedented market adoption of metabolic regulators.
Pipeline Restructuring
Major drug manufacturers are divesting from early-stage cardiovascular research to finance late-stage GLP-1 combination trials. The trend reflects projections of sustained high-margin growth in metabolic disease management.